Sirt1 counteracted the activation of STAT3 and NF-κB to repress the gastric cancer growth

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 12, 2014, Pages 5050-5058

  Lu, Juan Juan ^a   Zhang, Li Ping ^a   Chen, Xiang ^a   Lu, Qi Ming ^a   Yang, Yu Xia ^a   Liu, Jing Ping ^a   Ma, Xin ^a  

^a GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Acetylation; Activation; Gastric cancer; NF B; Sirtuin 1; STAT3

Indexed keywords

BETA GALACTOSIDASE; CHOLECYSTOKININ OCTAPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; NICOTINAMIDE; RESVERATROL; SENESCENCE ASSOCIATED BETA GALACTOSIDASE; SIRTUIN 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ACETALIZATION; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENESCENCE; STOMACH CANCER; WESTERN BLOTTING;

RICE STRIPE VIRUS;

EID: 84921488227     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Zabaleta J. Multifactorial etiology of gastric cancer. Methods Mol Biol 2012; 863: 411-435.
2. Brenner H, Rothenbacher D and Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009; 472: 467-477.
3. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu K., Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ; Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279-287.
4. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK and Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 2013; 14: e535-547.
5. Correa P. Is gastric cancer preventable? Gut 2004; 53: 1217-1219.
6. Yuan Z, Zhang X, Sengupta N, Lane WS and Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell 2007; 27: 149-162.
7. Finkel T, Deng CX and Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
8. Bosch-Presegue L and Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011; 2: 648-662.
9. Yuan H, Su L and Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013; 6: 1399-1416.
10. Lo Sasso G, Ryu D, Mouchiroud L, Fernando SC, Anderson CL, Katsyuba E, Piersigilli A, Hottiger MO, Schoonjans K and Auwerx J. Loss of sirt1 function improves intestinal anti-bacterial defense and protects from colitis-induced colorectal cancer. PLoS One 2014; 9: e102495.
11. Chen X, Hokka D, Maniwa Y, Ohbayashi C, Itoh T and Hayashi Y. Sirt1 is a tumor promoter in lung adenocarcinoma. Oncol Lett 2014; 8: 387-393.
12. Liang Z, Yang Y, Wang H, Yi W, Yan X, Yan J, Li Y, Feng Y, Yu S, Yang J, Jin Z, Duan W and Chen W. Inhibition of SIRT1 Signaling Sensitizes the Antitumor Activity of Silybin against Human Lung Adenocarcinoma Cells In Vitro and In Vivo. Mol Cancer Ther 2014; 13: 1860-1872.
13. Hwang BJ, Madabushi A, Jin J, Lin SY and Lu AL. Histone/protein deacetylase SIRT1 is an anticancer therapeutic target. Am J Cancer Res 2014; 4: 211-221.
14. Ming M, Soltani K, Shea CR, Li X and He YY. Dual role of SIRT1 in UVB-induced skin tumorigenesis. Oncogene 2014; [Epub ahead of print].
15. Yang Q, Wang B, Zang W, Wang X, Liu Z, Li W and Jia J. Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS One 2013; 8: e70627.
16. Yang Q, Wang B, Gao W, Huang S, Liu Z, Li W and Jia J. SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-kappaB/Cyclin D1 signaling. Mol Cancer Res 2013; 11: 1497-1507.
17. Zhu H, Xia L, Zhang Y, Wang H, Xu W, Hu H, Wang J, Xin J, Gang Y, Sha S, Xu B, Fan D, Nie Y and Wu K. Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS One 2012; 7: e31431.
18. Li HJ, Che XM, Zhao W, He SC, Zhang ZL, Chen R, Fan L and Jia ZL. Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop. Oncol Rep 2013; 30: 2153-2160.
19. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW and Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 2008; 105: 3374-3379.
20. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015.
21. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M and Guarente L. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-563.
22. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho MH, Park GH and Lee KH. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007; 39: 8-13.
23. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL and Gao Q. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 2009; 11: 492-500.
24. Bernier M, Paul RK, Martin-Montalvo A, Scheibye-Knudsen M, Song S, He HJ, Armour SM, Hubbard BP, Bohr VA, Wang L, Zong Y, Sinclair DA and de Cabo R. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J Biol Chem 2011; 286: 19270-19279.
25. Yuan ZL, Guan YJ, Chatterjee D and Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307: 269-273.
26. Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
27. Yu H and Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
28. Hori YS, Kuno A, Hosoda R and Horio Y. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One 2013; 8: e73875.
29. Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Loffler D, Horn F, Trumper L and Kube D. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005; 19: 936-944.
30. Chen LF, Mu Y and Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 2002; 21: 6539-6548.
31. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-2302.
32. Li T, Wang W, Chen H, Li T and Ye L. Evaluation of anti-leukemia effect of resveratrol by modulating STAT3 signaling. Int Immunopharmacol 2010; 10: 18-25.
33. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M and Aggarwal BB. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003; 102: 987-995.
34. Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES and Janz S. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer 2010; 9: 97.
35. Evan GI and Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
36. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R and Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-1283.
37. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S and Zender L. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479: 547-551.
38. Giraud AS, Menheniott TR and Judd LM. Targeting STAT3 in gastric cancer. Expert Opin Ther Targets 2012; 16: 889-901.
39. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L and Greene WC. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005; 25: 7966-7975.
40. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M and Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999; 189: 63-73.
41. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A and Koya D. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 2007; 282: 151-158.